RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • December 14th, 2022 • Immix Biopharma, Inc. • Pharmaceutical preparations
This Research and License Agreement (this “Agreement”) is entered into on November 27, 2022 (the “Effective Date”), by and between Hadasit Medical Research Services & Development, Ltd. of Jerusalem Bio Park, Hadassah Ein-Kerem Medical Center, P.O.B. 12000, Jerusalem 91120, Israel (“Hadasit”), BIRAD – Research and Development Company Ltd. of Bar Ilan University, Bldg. 102, Ramat Gan 5290002, Israel (“BIRAD”) (Hadasit and BIRAD, collectively, the “Licensors”) and Immix Biopharma Cell Therapy, Inc., a Delaware corporation, having a place of business at 11400 West Olympic Blvd Suite 200 Los Angeles, CA 90064 United States (“Company”). Each of Company and Licensor may be referred to as a “Party” and together as the “Parties”.
